Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - January 27, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (" Sharp " or the " Company "), a pre-clinical stage biotechnology company specializing in small molecule drugs to treat genetic diseases, is pleased to announce the successful completion of its previously announced consolidation of its common shares (the " Common Shares ") on the basis of one (1)... Read More

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - January 16, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (" Sharp " or the " Company "), a pre-clinical stage biotechnology company specializing in small molecule drugs to treat genetic diseases, announces that its board of directors has approved a consolidation (the " Consolidation ") of the Company's issued and outstanding common shares (the " Common Shares... Read More